Immunovaccine Inc.
1819 Granville Street
Suite 303
Halifax
Nova Scotia
B3J 3R1
Canada
Tel: 902-492-1819
Fax: 902-492-0888
Website: http://www.imvaccine.com/
Email: info@imvaccine.com
70 articles about Immunovaccine Inc.
-
Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology and Enhanced Efficacy in Slowing Tumor Progression
1/31/2018
In the study, published on January 27, 2018, researchers tracked how the cancer peptides were trafficked from the injection site to immunogenic activation in the lymph nodes
-
Immunovaccine Names Joseph Sullivan, Experienced Global Pharmaceutical and Vaccine Executive, as Senior Vice President, Business Development
1/18/2018
Mr. Sullivan brings over 25 years of global pharmaceutical and vaccine experience with Merck & Co, Inc. to his new position at Immunovaccine.
-
Top 6 Biotech Stocks of 2017
12/20/2017
When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates. -
Immunovaccine and UConn Health Extend Collaboration to Support Advancement of Patient-Specific Immunotherapies to the Clinic
12/7/2017
The collaboration is part of Immunovaccine’s DPX-NEO program.
-
Immunovaccine to Hold Webcast and Conference Call to Discuss Clinical Data From Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer
12/5/2017
The purpose of this conference call is to share top-line clinical data from its ongoing Phase 1b trial evaluating the safety and efficacy of Immunovaccine’s lead immuno-oncology candidate.
-
Immunovaccine Announces Positive Clinical Data from Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer
12/5/2017
Initial results from ten evaluable patients in the DPX-Survivac plus 100 mg epacadostat dosing cohort demonstrate a disease control rate of 70%.
-
Immunovaccine and Leidos Expand Collaboration to Develop Malaria Vaccines Formulated in DepoVax
11/21/2017
The two companies will expands its collaboration to develop preventative, peptide-based malaria vaccine candidates.
-
Immunovaccine Announces Third Quarter 2017 Financial Results
11/10/2017
The net loss and comprehensive loss of $2,122,000 or $0.02 per basic and diluted share for the quarter ended September 30, 2017 was $223,000 higher than the net loss and comprehensive loss for the three months ended September 30, 2016.
-
Immunovaccine Announces Regulatory Clearance for Phase II Clinical Trial Evaluating DPX-Survivac in Combination With Merck’s Checkpoint Inhibitor Pembrolizumab in DLBCL
11/8/2017
This trial is designed to evaluate the safety and efficacy of Immunovaccine’s lead candidate along with Merck’s pembrolizumab and low-dose cyclophosphamide in this patient population.
-
Immunovaccine Receives an Extension to the Maturity Date of its $5M Loan Until 2020
10/17/2017
The new maturity date is now August 9, 2020.
-
Immunovaccine Announces Achievement Of Milestones In Collaboration With Zoetis To Develop Veterinary Vaccines
8/31/2017
-
Immunovaccine Announces Financial Results For Quarter Ended June 30, 2017
8/9/2017
-
Immunovaccine Achieves Breakthrough In Support Of Developing Personalized Cancer Immunotherapies
7/12/2017
-
Immunovaccine Announces Closing Of $10 Million Bought Deal Offering
6/21/2017
-
Immunovaccine Forms Inaugural Scientific And Clinical Advisory Committee
6/14/2017
-
Immunovaccine Announces $10 Million Bought Deal Offering
5/31/2017
-
Immunovaccine Announces Positive Year-Long Immunogenicity Data From Phase I Clinical Trial For Respiratory Syncytial Virus Vaccine Candidate
4/12/2017
-
Immunovaccine Appoints Seasoned Financial Executive Pierre Labbe As CFO
2/3/2017
-
Immunovaccine Names Acting Chief and CBO as Permanent CEO
4/13/2016
-
Immunovaccine Inc. And Leidos Join Forces To Develop A Zika Virus Vaccine Candidate
4/7/2016